A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

Merck KGaA’sMRK-1.94%decrease; red down pointing triangle shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than ...

Taking a new tack There's no word yet on the drug targets that will be explored in the Cerevance partnership, but Merck head of neuroscience discovery, Jason Uslaner, said that the collaboration ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...

Earlier in October, Jason Trennert, Strategas Research Partners ... beating its benchmark by 150 percentage points (see more ...

Jason Ritter co-stars in CBS’s hit legal drama “Matlock,” which follows Madeline “Matty” Matlock (Kathy Bates), a seemingly widowed and inexperienced ex-lawyer who takes a job at the ...

EF Hutton analyst Jason Kolbert initiated coverage of ImmunityBio ... Ivonescimab outperformed leading cancer drug Keytruda ...

“The use of the PET ligand for better understanding the disease process itself will be very valuable,” says Jason Uslaner, VP, Research Science at Merck. “What levels of alpha-synuclein and ...

which was founded in 2015 by Alice Zhang and Jason Chen. VRG50635 was discovered using Verge's AI-powered discovery platform ConVERGE which maps out the biological underpinnings of diseases using ...

In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

In this article, we are going to take a look at where Merck & Co. Inc. (NYSE ... Earlier in October, Jason Trennert, Strategas Research Partners chairman and CEO, joined CNBC to discuss the ...